Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran monotherapy in primary hypercholesterolemia
NCT05763875Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 5
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Mar 2023; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05763875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763875.